Microbot Medical (NASDAQ:MBOT) and NexGel (NASDAQ:NXGL) Financial Contrast

NexGel (NASDAQ:NXGL) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

Profitability

This table compares NexGel and Microbot Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NexGel	-28.54%	-64.29%	-29.64%
Microbot Medical	N/A	-21.84%	-20.71%

Risk & Volatility

NexGel has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.

Insider and Institutional Ownership

2.2% of NexGel shares are owned by institutional investors. Comparatively, 16.3% of Microbot Medical shares are owned by institutional investors. 23.4% of NexGel shares are owned by insiders. Comparatively, 4.7% of Microbot Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares NexGel and Microbot Medical”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NexGel	$11.42 million	0.35	-$3.00 million	($0.40)	-1.07
Microbot Medical	N/A	N/A	-$13.14 million	($0.26)	-6.77

NexGel has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than NexGel, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for NexGel and Microbot Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NexGel	1	0	1	0	2.00
Microbot Medical	1	1	2	1	2.60

NexGel currently has a consensus price target of $2.00, suggesting a potential upside of 365.12%. Microbot Medical has a consensus price target of $6.62, suggesting a potential upside of 276.42%. Given NexGel’s higher probable upside, analysts clearly believe NexGel is more favorable than Microbot Medical.

Summary

Microbot Medical beats NexGel on 9 of the 14 factors compared between the two stocks.

About NexGel

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.

About Microbot Medical

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.